Effect of С60 fullerenes on the intensity of colon damage and hematological signs of ulcerative colitis in rats

Water-Soluble Pristine C60 Fullerenes Inhibit Liver Fibrotic Alteration and Prevent Liver Cirrhosis in Rats

“…Indeed, we demonstrated the decrease of the extent of lipid and protein peroxidation and restoration activity of antioxidant defense enzyme GP under C 60 FAS action suggesting mitigation of oxidative stress. Similar changes of GP activity under the action of C 60 FAS have been demonstrated in [63] and corroborated with our previous results [16]. We can explain the upregulation of this enzyme with the ability of C 60 fullerene to scavenge ROS, creating therefore its optimal concentration for activating the enzyme.…”

“…Water-soluble C 60 fullerene is able to accumulate in rat liver [13] and prevent its acute toxic injury [14]. Additionally, in our previous studies, we demonstrated its ability to prevent not only acute but also chronic liver injury [15], to serve as an anti-inflammatory agent [16], and to inhibit liver fibrosis on acute and chronic cholangitis models [17] applying in small doses. Moreover, water-soluble C 60 fullerene is capable of reducing collagen deposition in the lungs of bleomycin-induced pulmonary fibrosis mice [18].…”

“…Oxidative Medicine and Cellular Longevity correspond to hepatic inflammation (2-6 weeks from the start of the study, i.e., the introduction of DEN), advanced fibrosis and cirrhosis (8-12 weeks from the start of the study), and malignant degeneration of liver cells (14-16 weeks from the start of the study) [21,22]. C 60 FAS was administered daily intraperitoneally in a volume corresponding to the dose of C 60 fullerene 0.25 mg/kg, which is considered as safe and effective as evidenced by our previous studies [15][16][17], starting 2 weeks after DEN administration (i.e., simultaneously with hepatotoxin CCl 4 ) for 8 and 13 weeks to explore its effect on the development of fibrosis and cirrhosis, respectively. Comparison groups were induced by appropriate solvents instead (Figure 1).…”

“…Therapeutic interventions ongoing clinical trials include efforts to minimize hepatic injury and inflammation (corticosteroids, ursodeoxycholic acid, and hepatocytes' apoptosis inhibitors), to inhibit liver fibrogenesis by enhancing or inhibiting target receptorligand interactions or intracellular signaling pathways (interferons, antioxidants, angiotensin-converting enzyme inhibitors, TGF-β antagonists, and multitargeted kinase inhibitors), and to promote resolution of fibrosis (HSC-specific targeting) [71]. As anti-inflammatory [16], hepatoprotective [14,15], and antifibrotic [17] effects of water-soluble pristine C 60 fullerene have been demonstrated, this nanoparticle could be considered as a promising antifibrotic agent for treating liver diseases associated with its fibrosis.…”

Carbon Nanomaterials Applied for the Treatment of Inflammatory Diseases: Preclinical Evidence

“…NF-B is a protein complex that controls cytokine production. It was clearly observed that the fullerene compound inhibited phosphorylation and effectively reduced nuclear Bone marrow-derived mast cells from C57BL/6 mice - [45] Fullerol Graft-versus-host disease -GVHD mouse model [46] Fullerene (aqueous solution) Ulcerative colitis -Acute colitis rat model [49] Fullerene (aqueous solution) Atopic dermatitis Ovalbumin-stimulated mouse splenocytes Atopic dermatitis mouse model [50] Functionalized fullerenes Rheumatoid arthritis BMMCs generated from FC RII-deficient mice and human fibroblasts from the synovium of RA patients K/BxN serum transfer arthritis mouse model and CIA mouse model [51] SWCNTs Inflammation RBL2H3 (rat basophilic leukemia cells)…”